Media stories about Diplomat Pharmacy (NYSE:DPLO) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.2621846967188 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
NYSE DPLO opened at $21.05 on Friday. Diplomat Pharmacy has a 1-year low of $14.23 and a 1-year high of $27.78. The company has a market capitalization of $1,608.78, a P/E ratio of 25.06 and a beta of 1.32. The company has a quick ratio of 0.66, a current ratio of 0.97 and a debt-to-equity ratio of 0.70.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business posted $0.08 EPS. Diplomat Pharmacy’s quarterly revenue was up .9% on a year-over-year basis. equities research analysts expect that Diplomat Pharmacy will post 0.93 EPS for the current fiscal year.
In related news, Director Philip R. Hagerman sold 2,150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $20.65, for a total value of $44,397,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 30.20% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.